RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). This is an ASCO ...
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback